MYELOPROLIFERATIVE NEOPLASMS
Clinical trials for MYELOPROLIFERATIVE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASMS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets rare blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called INCA033989, given alone or with another drug (ruxolitinib), in people with myeloproliferative neoplasms—a group of rare blood cancers. The main goals are to check safety and find the best dose. About 290 adults with certain genetic m…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
New hope for blood cancer: early trial of INCB160058 begins
Disease control Recruiting nowThis early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the best dose and watch…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 10:13 UTC
-
New combo therapy targets tough blood cancers
Disease control Recruiting nowThis early-phase study tests whether adding ivosidenib to the standard drug ruxolitinib is safe and effective for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 mutation. About 18 adults with these rare blood cancers will receive the combination to fin…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 10:09 UTC
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCA036978, in people with certain blood cancers (myeloproliferative neoplasms). The main goals are to check safety, find the right dose, and see how the drug works alone or with standard treatment. About 218 participants will take part.
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug combo targets rare blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug, INCA033989, alone or with another drug (ruxolitinib) in 225 adults with myeloproliferative neoplasms, a group of blood cancers. The main goal is to check safety and find the best dose. Participants must have a specific gene mutation (CALR)…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug trial aims to tame rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCA035784, in 120 adults with myeloproliferative neoplasms (MPNs), a group of blood cancers. The main goal is to check the drug's safety and find the right dose. Participants must have a specific gene mutation and have tried other treatme…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 10:14 UTC